基于肿瘤新抗原的晚期肝细胞癌过继免疫细胞治疗相关进展  

Progress of advanced hepatocellular carcinoma adoptive cell therapy based on tumor neoantigens

作　　者：王方舟[1] 张雯雯[1] 李崇辉[1] 卢实春[1] Wang Fangzhou;Zhang Wenwen;Li Chonghui;Lu Shichun(Faculty of Hepato-Pancreato-Biliary Surgery,Chinese PLA General Hospital,Institute of Hepatobiliary Surgery of Chinese PLA,Key Laboratory of Digital Hepatobiliary Surgery of Chinese PLA,Beijing 100853,China)

机构地区：[1]解放军总医院肝胆胰外科医学部解放军总医院肝胆外科研究所全军数字肝胆外科重点实验室,北京100853

出　　处：《中华肝胆外科杂志》2022年第9期708-712,共5页Chinese Journal of Hepatobiliary Surgery

摘　　要：晚期肝细胞癌恶性程度高,预后差,研究发现肝癌进展与肿瘤微环境中的免疫状态存在密切关系。过继免疫细胞治疗可通过给患者输注激活的特异性免疫细胞产生抗肿瘤作用,改善免疫抑制状态,是肿瘤治疗的研究热点,并在多种恶性肿瘤的治疗中展示出较好的效果,表现出了巨大的应用潜力。在肝细胞癌治疗方面基于肿瘤新抗原的过继免疫细胞治疗成为新的热点,而其应用方式、安全性与有效性评估、疗效预测及评价成为亟待解决的问题。本文旨在通过介绍晚期肝细胞癌过继免疫细胞治疗相关进展,并阐述未来需要解决的问题。Advanced hepatocellular carcinoma has a high degree of malignancy and poor prognosis.Studies showed that there is a close relationship between the progression of hepatocellular carcinoma and the immune status in tumor microenvironment.Adoptive cell therapy showed anti-tumor effects and improve immunosuppression by infusing patients with activated specific immune cells,which become a central issue in tumor therapy and shown promising effects in the treatment of various malignant tumors,indicating great application potential.Adoptive cell therapy based on neoantigen may become a new hot spot in the treatment of hepatocellular carcinoma,and their application,safety and effectiveness evaluation,efficacy prediction and assessment have become urgent issues to be solved.The purpose of this article is to introduce the progress related to adoptive cell therapy for advanced hepatocellular carcinoma and elaborate the problems that need to be solved in the future.

关 键 词：癌 肝细胞 过继免疫细胞治疗 肿瘤新抗原 肿瘤疫苗 

分 类 号：R735.7[医药卫生—肿瘤]